EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Use of Janus Kinase Inhibitors in the Treatment of Genodermatoses: A Systematic Review

Pin-Chun Chen, Chih-Chiang Chen, Sheng-Hsiang Ma, Tai-Li Chen

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/5123844 ↗
AbstractBibliografische Angaben

Abstract

Introduction Genodermatoses are rare inherited skin disorders with limited treatment options. Emerging evidence suggests Janus kinase (JAK) inhibitors may offer therapeutic benefits by modulating underlying immune and inflammatory pathways. This study aims to systematically review the efficacy and safety of JAK inhibitors in treating genodermatoses, including epidermolysis bullosa (EB), Netherton syndrome, and Hailey‐Hailey disease. Methods A comprehensive literature search identified case reports and series evaluating JAK inhibitor therapy in genodermatoses. Quality assessment was performed using the Joanna Briggs Institute Critical Appraisal Tools for Case Reports, demonstrating high methodological quality across included studies. Results Twenty studies involving patients with EB subtypes (especially dystrophic EB), Netherton syndrome, and other inherited dermatoses reported clinical improvement following treatment with JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib. Outcomes included reduction in pruritus, skin inflammation, and lesion severity, with notable improvements in quality‐of‐life measures. Treatment regimens varied (e.g., tofacitinib 5 mg twice daily, baricitinib 2 mg once daily, and upadacitinib 15 mg once daily) with follow‐up ranging from weeks to months. Laboratory monitoring showed stable profiles without significant adverse events. Reports of adverse events were rare or absent across studies, indicating favorable safety profiles. Conclusions JAK inhibitors represent a promising therapeutic avenue for genodermatoses characterized by immune dysregulation and chronic inflammation. While preliminary data are encouraging, further controlled studies are warranted to establish long‐term efficacy and safety. These findings support expanded clinical investigation of JAK inhibition in managing inherited skin disorders.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →